OPEN ACCESS Freely available online

ISSN: 2157-7560
Journal of
Vaccines & Vaccination

Short Communication

Scientific Progress in Viral Vaccine Development and Public Health Protection

Celestine Moreau*

Department of Molecular Virology, Alpine Coast University, Marseille, France

DESCRIPTION

Viral vaccine development has played a major role in reducing infectious diseases that once caused widespread illness and high mortality rates across the world. Vaccines prepared against viruses such as measles, polio, influenza, hepatitis and rabies have saved millions of lives through organized immunization programs and medical research efforts. The process of developing viral vaccines combines virology, immunology, biotechnology and clinical medicine to produce safe and effective methods for disease prevention. Over the past century, scientific advances have improved vaccine production techniques, shortened development timelines and expanded protection against emerging viral threats [1,2].

Viruses are microscopic infectious agents that depend on host cells for survival and replication. Once inside the body, viruses invade healthy cells and use cellular machinery to reproduce. Some viral infections produce mild symptoms, while others may result in severe organ damage, long-term disability or death. Vaccines help the immune system recognize viral components before natural exposure occurs. This preparation allows immune cells to respond rapidly during future infections, reducing disease severity or preventing illness completely.

The earliest viral vaccines were developed using weakened or inactivated forms of viruses. Live attenuated vaccines contain viruses that have been modified so they produce immune responses without causing serious disease in healthy individuals. Examples include vaccines against measles, mumps, rubella and yellow fever. These vaccines often provide strong and long-lasting immunity because they closely resemble natural infection [3]. However, they require careful production and storage procedures to maintain safety and effectiveness.

Inactivated vaccines use viruses that have been killed through chemical or physical methods. Although these vaccines cannot reproduce inside the body, they still stimulate immune responses against viral antigens. Inactivated vaccines are commonly used for diseases such as rabies, hepatitis A and some influenza strains. They are generally considered safe for individuals with weakened immune systems, though multiple doses or booster injections may be necessary to maintain protection over time[4,5].

Advances in biotechnology have expanded viral vaccine development beyond traditional methods. Recombinant protein vaccines use laboratory-produced viral proteins instead of whole viruses. These vaccines reduce the possibility of infection because they contain only selected viral components. Scientists have successfully used recombinant technology for hepatitis B vaccines and several newer vaccine candidates [6]. Such methods allow researchers to target specific viral structures that stimulate strong immune responses.

Messenger Ribonucleic Acid (RNA) technology has become one of the most discussed developments in modern vaccine research. Messenger RNA vaccines contain genetic instructions that direct human cells to temporarily produce harmless viral proteins. Once these proteins are produced, the immune system recognizes them and generates protective responses. This method gained worldwide attention during the COVID-19 pandemic because mRNA vaccines were developed and distributed within a relatively short period. Researchers continue studying the use of this technology for influenza, rabies, cytomegalovirus and other viral diseases [7,8].

Viral vector vaccines represent another important advancement in vaccine science. These vaccines use modified viruses as carriers to deliver genetic material from target pathogens into human cells. The carrier viruses are engineered so they cannot cause severe disease. Once administered, cells produce viral antigens that stimulate immunity. Viral vector methods have been investigated for diseases such as Ebola, COVID-19 and Zika virus infection. This technology offers flexibility for rapid vaccine design during emerging outbreaks [9,10].

CONCLUSION

Emerging viral diseases continue to create demand for new vaccines. Viruses such as SARS-CoV-2, Nipah virus and avian influenza strains demonstrate how rapidly infectious diseases can

Correspondence to: Celestine Moreau, Department of Molecular Virology, Alpine Coast University, Marseille, France, E-mail: celestine.moreau.virology@acu-france.org

Received: 17-Jun-2025, Manuscript No. JVV-26-31578; **Editor assigned:** 19-Jun-2025, Pre QC No. JVV-26-31578 (PQ); **Reviewed:** 03-Jul-2025, QC No. JVV-26-31578; **Revised:** 10-Jul-2025, Manuscript No. JVV-26-31578 (R); **Published:** 17-Jul-2025, DOI: 10.35248/2157-7560.26.16.616.

Citation: Moreau C (2026). Scientific Progress in Viral Vaccine Development and Public Health Protection. J Vaccines Vaccin. 16:616.

spread across populations. Climate change, international travel, urbanization and environmental disruption may increase opportunities for viral transmission between animals and humans. Rapid vaccine development systems are therefore becoming increasingly valuable for global preparedness against future outbreaks. Research in viral vaccine development continues expanding through improvements in genetic engineering, immune system analysis and biotechnology manufacturing. Scientists are studying universal influenza vaccines, needle-free administration methods and vaccines that provide broader protection against multiple virus strains.

REFERENCES

1. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584(7821): 353-363.
2. Ricke DO. Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol. 2021;12:640093.
3. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus: Atypical measles in children previously immunized with inactivated measles virus vaccines. Jama. 1967;202(12):1075-1080.
4. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89(4):449-463.
5. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018 Jul;379(4):327-340.
6. Pedersen NC, Boyle JF. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res. 1980;41(6):868-876.
7. Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis. 1981;4(2):175-189.
8. Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol. 2010;17(12):1829-1835.
9. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes. Lancet Infect Dis. 2010;10(10):712-722.
10. Hawkes RA. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci. 1964;42(4):465-482.